[The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B

StephenW

Zhonghua Gan Zang Bing Za Zhi. 2011 Oct;19(10):743-6. doi: 10.3760/cma.j.issn.1007-3418.2011.10.006.
[The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma]. [Article in Chinese]
Pei YZ, Han T, Ma XY, Li Y, Xing J, Song ZL.
SourceDepartment of Hepatology, Tianjin Institute of Hepatobiliary Disease, Tianjin, China.

AbstractOBJECTIVE: To investigate the discrepancy of HBsAg titre and correlation of HBV DNA levels among patients with chronic hepatitis B (CHB), HBV-related liver cirrhosis (LC) and hepatocellular carcinoma (HCC).
METHODS: HBsAg titre and HBV DNA in serum samples were measured among 47 CHB, 72 LC and 54 HCC cases using Abbott chemiluminescence and fluorescence quantitative PCR, respectively. Statistical analyses among multiple groups, between two groups and about the correlation were performed using Kruskal-Wallis test, Mann-Whitney U test and Spearman test, respectively.
RESULTS: The median HBsAg titre level in serum samples decreased from 2361.10 IU/ml in CHB cohort to 1001.64 IU/ml in LC cohort and 594.35 IU/ml in HCC cohort, suggesting a statistically significant difference (x2 = 24.394, P less than 0.05). Moreover, HBsAg titre in CHB group was significantly higher than that in LC group ( Z = -3.754, P less than 0.05). CHB patients had significantly higher HBsAg titre than HCC cases ( Z = -4.630, P less than 0.05). However, there was no statistically significant difference in HBsAg titre between LC and HCC group. Among HBeAg positive patients, HBsAg titre decreased from 3259.83 IU/ml in CHB group to 1077.30 IU/ml in LC group and 789.72 IU/ml in HCC group, indicating a significant difference (x2 = 15.643, P less than 0.01). Among HBeAg negative patients, HBsAg titre declined from 1669.00 IU/ml in CHB group to 1001.64 IU/ml in LC group and 582.05 IU/ml in HCC group, suggesting of a significant difference (x2 = 6.423, P less than 0.05). Positive correlation between HBsAg titre and HBV DNA was found in CHB ( r = 0.297, P less than 0.05), LC (r = 0.346, P less than 0.05) and HCC (r = 0.452, P less than 0.05), respectively.
CONCLUSION: HBsAg titre level in serum decreased progressively from CHB to LC and HCC group. There were positive correlations between HBsAg titre and HBV DNA level in CHB, LC and HCC.

StephenW

中华肝脏病杂志。 2011 10 19（10）:743-6。 DOI：10.3760/cma.j.issn.1007-3418.2011.10.006。
这种差异与慢性肝炎，HBV相关的肝硬化和肝癌乙患者乙肝表面抗原滴度和HBV DNA。
[文章在中国]
裴逸曾，韩ţ，马杏垣，李勇，邢J，宋：ZL。
源

肝病，天津市肝胆疾病研究所，天津，中国。
抽象
目的：

为了探讨慢性乙型肝炎（CHB），HBV相关性肝硬化（LC）和肝细胞癌（HCC）患者的乙肝表面抗原滴度和HBV DNA水平的相关性的差异。
方法：

乙肝表面抗原滴度和血清中HBV DNA测定其中47例CHB，72 LC和54例肝癌使用雅培化学发光和荧光定量PCR，分别。使用Kruskal-Wallis检验的Mann-Whitney U检验和Spearman测试，分别在多个组，两组有关的相关性，进行统计分析。
结果：

HBsAg的血清标本的滴度水平的中位数下降至2361.10 IU /毫升慢性乙型肝炎队列1001.64 IU /毫升在立法会的队列和594.35 IU /毫升肝癌队列，提出了统计学显着性差异（χ2= 24.394，磷小于0.05）。此外，在CHB组的乙肝表面抗原滴度明显高于LC组（z = -3.754，P值小于0.05），高。慢性乙型肝炎患者的HBsAg滴度显着高于肝癌病例（z = -4.630，P值小于0.05）。然而，LC和HCC组之间的差异是在HBsAg滴度无统计学意义。其中HBeAg阳性患者，乙肝表面抗原滴度下降IU /毫升在CHB组从3259.83 1077.30 IU /毫升LC组​​和789.72 IU /毫升在肝癌组，显示出显着性差异（X2 = 15.643，P减比0.01）。其中HBeAg阴性患者，乙肝表面抗原滴度下降至1669.00 IU /毫升CHB组1001.64 IU /毫升LC组​​和582.05 IU /毫升在肝癌组，一个显着性差异（χ2= 6.423，磷小于0.05）建议。在慢性乙型肝炎（R = 0.297，P值小于0.05），LC发现乙肝表面抗原滴度和HBV DNA之间呈正相关（R = 0.346，P小于0.05）和肝癌（R = 0.452，P小于0.05），分别。
结论：

从慢性乙型肝炎LC和HCC组的血清中乙肝表面抗原滴度水平逐步下降。有乙肝表面抗原滴度和HBV DNA水平在CHB，LC和HCC之间的正相关。